A picornavirus is a virus belonging to the family Picornaviridae, a family of viruses in the order Picornavirales. Vertebrates, including humans, serve as natural hosts. Picornaviruses are nonenveloped viruses that represent a large family of small, cytoplasmic, plus-strand RNA (~7.5kb) viruses with a 30-nm icosahedral capsid. Its genome does not have a lipid membrane. Picornaviruses are found in mammals and birds. There are currently 80 species in this family, divided among 35 genera. Notable examples are Enterovirus (including Rhinovirus and Poliovirus), Aphthovirus, Cardiovirus, and Hepatovirus genera. The viruses in this family can cause a range of diseases including paralysis, meningitis, hepatitis and poliomyelitis. Picornaviruses are in Baltimore IV class. Their genome single-stranded (+) sense RNA is what functions as mRNA after entry into the cell and all viral mRNA synthesized is of genome polarity. The mRNA encodes RNA dependent RNA polymerase. This polymerase makes complementary minus strands of RNA, then uses them as templates to make more plus strands. So, an overview of the steps in picornavirus replication are in order: attachment, entry, translation, transcription/genome replication (one and the same process), assembly and exit.
Agouron Pharmaceuticals LLC
Agouron Pharmaceuticals, Inc.’s operations consists of the discovery, development, manufacture, and marketing of therapeutic products engineered to inactivate proteins, which play roles in cancer, AIDS, and other serious diseases. Its product, VIRACEPT®, was a drug for the treatment of HIV infection. Agouron Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.
Medicine
Respiratory disease
Neurological disorder
Central nervous system
Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.
Medicine
Humalog Mix
Major depressive disorder
Breast cancer
Insulin
Clinical trial
Oncology drugs
Insulin pen
Idiopathic short stature
Insulin aspart
Generalized anxiety disorder
Bipolar I disorder
Peripheral neuropathic pain
Bulimia nervosa
Panic disorder
Growth hormone deficiency
Endocrinology
Fibromyalgia
Monoclonal antibody
Wellstat Biologics Corp.
http://www.wellstatbiologics.com
|
Wellstat Biologics Corp. is a private company headquartered in Gaithersburg, MD. The firm operates as development and commercialization of biological agents.
Medicine
Cancer immunotherapy
Biological agent
Immunotherapy
Oncology drugs
Medicago Inc., a biotechnology company, focuses on the research, development, production, and commercialization of vaccines in Canada. The company develops its vaccines based on its proprietary technologies, including the plant-based Proficia technology and Virus-Like Particles (VLP) technology. Its product candidate includes H5N1 pandemic influenza VLP vaccine, which has completed a Phase I human clinical trial. The company is also developing H1N1 VLP vaccine for Influenza A/California/04/09 virus; and seasonal influenza vaccines. Medicago Inc. has collaboration agreements with Viridis S.A.; Genopole biopark to manufacture pandemic and seasonal influenza vaccines; and Philip Morris International to produce a therapeutic protein with a humancompatible glycosylation pattern. The company was incorporated in 1997 and is headquartered in Quebec City, Canada.
Medicine
Pandemic
Influenza vaccine
Coronavirus disease 2019 (COVID-19)
Therapeutic protein
Infection drug
Biopharmaceutical
Coronavirus
Medicago
Biotechnology
Glycosylation
Clinical trial
Drug discovery
Gastrointestinal agent
Drug development
Antiviral drug
Toxoid
DNA vaccination
Genomics
Sentinext Therapeutics Sdn. Bhd.
Sentinext Therapeutics Sdn. Bhd. develops vaccines and therapeutics for tropical infectious diseases. Its pharmaceutical research and development focuses on EV71, polio, influenza and dengue diseases. The company was founded by Mary Jane Cardosa and Peter Samuel Wulff in 2009 and is headquartered in Penang, Malaysia.
Infection drug
Medicine
Clinical trial
Viralytics Pty Ltd.
http://www.viralytics.com
|
Viralytics is an Australian biotechnology company, listed on the Australian Stock Exchange (ASX:VLA) and is quoted on the OTC market (VRACY). Focused on developing oncolytic virotherapy for the treatment of a wide range of cancers Viralytics' headquarters are in Sydney, Australia and research and operations are in Newcastle, Australia.
Oncolytic virotherapy makes use of the cancer destroying capabilities of a range of benign viruses. The potential of oncolytic virotherapy is the ability to treat cancers more effectively and with minimum side-effects.
Virotherapy
Pharmacy and Therapeutics
Immunotherapy
Oncology drugs
Medicine
Cancer
Cancer immunotherapy
Biotechnology
Pembrolizumab
Drug development
Virus
Biopharmaceutical
Drug discovery
Markets pharmaceutical specialties & personal products
Biota Scientific Management Pty Ltd.
Biota Scientific Management Pty Ltd., a subsidiary of Vaxart, Inc., is an Australian company located in Notting Hill that develops anti-infective drugs.
Scientific management
Medicine
Drug
Alios BioPharma, Inc.
http://www.aliosbiopharma.com
|
Alios is discovering and developing novel therapeutic agents based on three platform technologies including: small molecule activators of innate immunity antiviral pathways (RNase L activation), phosphate protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons (Glycoferonâ). This complementary group of platform technologies has the potential to generate a number of distinct therapeutic products to treat a variety of serious viral infections such as chronic hepatitis B and C, HIV infection, and respiratory viruses (e.g. pandemic influenza) and emerging viral diseases (e.g. SARS).
Medicine
Antiviral therapy
Ritonavir
Biopharmaceutical
Uridine
Nucleoside Analogs
Rhinovirus
Metered-dose inhaler
Spirometer
Resuscitator
Tracheal tube
Positive airway pressure device
Nebulizer
Nucleoside
Medical ventilator
Oxygen concentrator
Nucleotide
Inhaler
Orphan drug
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Dosage form
Medicine
Clinical trial
Oncology
Oncology drugs
Cardiovascular agent
Monoclonal antibody
Immunotherapy
Inhaler
Adalimumab
Genomics
Bronchodilator
Rituximab
Biopharmaceutical
Dry-powder inhaler
Metered-dose inhaler
Optometry
Gastrointestinal agent
Bevacizumab
Apodemus AB is a Swedish private company located in Solna that develops antiviral treatments and diagnostic tools for viral infections.
Drug development
Medicine
Drug discovery
Insulin
University Court of the University of St. Andrews
http://www.st-andrews.ac.uk
|
GlaxoSmithKline Biologicals SA
Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever
Medicine
Rubella
Hepatitis
Typhoid fever
Quality control
Clinical trial
Cytoclonal Pharmaceutics, Inc.
Develops pharmaceutical products for polycystic kidney disease
Polycystic kidney disease
Botanical drug
Herb
Novavax is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated the development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’s proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.
Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.
ISCOM
Medicine
Adjuvant
Conjugate vaccine
Toxoid
Coronavirus disease 2019 (COVID-19)
Infection drug
Coronavirus
DNA vaccination
Clinical trial
Agricultural science
Severe acute respiratory syndrome
Antiviral drug
MF59
Nanotechnology
Nanomedicine
Drug development
Drug discovery
Manufactures pharmaceuticals
Institut Pasteur
http://www.pasteur.fr/en
|
The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.
Public health
Genome
Genomics
Epigenomics
Epigenetics
Genomic medicine
Clinical research
Cell therapy
Drug discovery
Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.
Blood testing
Biology
Drug discovery
Biopharmaceutical
Biotechnology
Blood transfusion
Immunotoxin
Daclizumab
Nivolumab
Peramivir
Interleukin 2
Zanamivir
Oseltamivir
Vemurafenib
Paclitaxel
Sulfuric acid
Ipilimumab
Interleukin
Immunosuppressive drug
Antibody
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
Biopharmaceutical
Drug
Medicine
Livestock
Clinical trial
Oncology drugs
Biotechnology
Monoclonal antibody
Genomics
Cardiovascular agent
Immunotherapy
Drug discovery
Cell culture
Infection drug
Infertility
Gastrointestinal agent
Laboratory testing
Antiviral drug
People also interested in
Agricultural scienceInsulinPublic healthClinical trialCell therapyBlood testingTracheal tubeMedicineOptometryDrug development